25 1 57. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8. 58. Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol 2005;1:143-9. 59. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, doubledummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24. 60. Grunberg SM, Warr D, Gralla RJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011;19 Suppl 1:S43-7. 61. Ng TL, Hutton B, Clemons M. Chemotherapy-Induced nausea and vomiting: time for more emphasis on nausea? The Oncologist 2015;20:57683. 62. Janelsins MC, Tejani MA, Kamen C et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 2013;14:757-66. 63. Roila F, Molassiotis A, Herrstedt J et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapyand radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27(suppl 5):v119-v33. 64. Hesketh PJ, Kris MG, Basch E et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35:3240-61. 65. Damian S, Celio L, De Benedictis E et al. Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. Oncology 2013;84:3717. 66. Ito Y, Tsuda T, Minatogawa H et al. Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in highemetogenic chemotherapy. J Clin Oncol 2018;36:1000-6. 67. Okada Y, Oba K, Furukawa N et al. Oneday versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-Induced nausea and vomiting: a systematic review and individual patient data-based metaanalysis. The Oncologist 2019;24:15931600. 68. Celio L, Bonizzoni E, Zattarin E et al. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 2019;19:1268. 69. Aapro M, Fabi A, Nolè F et al. Doubleblind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:10838. 70. Celio L, Frustaci S, Denaro A et al; Italian Trials in Medical Oncology Group. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011;19:1217-25.
RkJQdWJsaXNoZXIy MjY0ODMw